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Abstract 
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin’s 
lymphoma. Patients who fail conventional therapy (~50%) have a poor 
prognosis and few treatment options. It is essential to understand the 
underlying biological processes, the progression of the disease, and utilize 
this information to develop new therapeutics.  
DLBCL patients with high C-MYC expression have a poor prognosis and new 
therapeutics for these patients are needed. This thesis describes work testing 
the hypothesis that JQ1, which can indirectly inhibit C-MYC in some tumors, 
can be used as an effective treatment for DLBCL. Some tumors have an 
unknown mechanism causing high C-MYC expression, leading me to 
investigate the underlying mechanisms. YY1 is a transcriptional regulator of c-
Myc and has been implicated in DLBCL and as a potential regulator of the 
germinal center (GC) reaction. DLBCL arises from GC cells or post-GC cells. 
I tested the hypothesis that YY1 regulates the GC reaction. SMURF2 is an 
E3-ubiquitin ligase for YY1 and a tumor suppressor for DLBCL. I was 
interested in examining the mechanism underlying the suppression of DLBCL 
by SMURF2 leading to the hypothesis that SMURF2 regulates the GC. 
This thesis shows JQ1 leads to cell death and cellular senescence in human 
DLBCL cells. I conclude that BRD4 inhibition by JQ1 or derivatives could 
provide a new therapeutic avenue for DLBCL patients. I also show loss of 
YY1 perturbs the GC by decreasing the dark zone and increasing apoptosis. 
Finally I show modulation of SMURF2 does not affect the GC, suggesting 
SMURF2 utilizes a different mechanism to act as a tumor suppressor and 
may not modulate YY1 in the context of the GC. 
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CHAPTER I: Introduction 
Diffuse Large B-cell Lymphoma 
Diffuse Large B-cell Lymphoma (DLBCL) is the most common non-
Hodgkin’s lymphoma, accounting for 30-40% of diagnoses(1, 2). 
Approximately 50% of patients eventually fail the conventional treatment, a 
combination therapy that includes chemotherapeutic agents doxorubicin, 
cyclophosphamide, and vincristine, prednisone, and targeted anti-CD20 
monoclonal antibody rituximab, termed R-CHOP. The inclusion of rituximab, 
which specifically ablates B cells, improves the cure rate of DLBCL by 10-
15%, indicating the benefit of targeted therapies(3). For patients who either 
do not respond or relapse after treatment, prognosis is poor and few 
treatment options outside of stem cell transplant exist(3, 4). Unfortunately, the 
advanced age of patients with DLBCL predisposes them to comorbidities and 
confounding factors, which prevent them from tolerating high doses of 
chemotherapy and also render them ineligible for stem cell transplant. Recent 
studies have focused on understanding the underlying genetics of DLBCL in 
an effort to discover specific targets for new therapeutics, which may 
decrease the need for high doses of chemotherapy or increase the overall 
survival rate of patients(5) (5).  
DLBCL has been separated into three distinct subtypes, termed the 
cell of origin classification, by gene expression profiling: activated B-cell-like 
(ABC), germinal center B-cell-like (GCB), and primary mediastinal B-cell 
lymphoma (PMBL) (6–10). These subtypes differ in molecular features and 
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cell of origin, each arising from distinct molecular processes that ultimately 
lead to neoplastic transformation. The ABC subtype has a gene expression 
signature that is similar to activated peripheral blood B cells, while the GCB 
subtype is similar to germinal center B cells (described below) and PMBL 
subtype arises from thymic B cells(6). Patients with ABC subtype have a 
worse prognosis than those with GCB subtype(6).  
Mutations in EZH2 and chromosomal translocations of BCL2, which 
leads to decreased apoptosis or C-MYC, leading to increased proliferation, 
are more common in the GCB subtype(7, 11–13). Alterations in 
BLIMP1/PRDM1, which regulates B cell differentiation(14–16), and various 
mutations leading to activation of the NF-κB pathway(17–21), are associated 
with the ABC subtype. Common to both GCB and ABC subtypes are BCL6 
translocations(22, 23) and mutations in CREBBP and EP300(24). Additional 
recurrent mutations in DLBCL have been identified recently(24–28), although 
the ability of these mutations to directly lead to lymphomagenesis has not 
been studied experimentally. In particular, a number of reports have 
highlighted the incidence of both C-MYC translocations (8.8-11%) and 
increased protein levels of C-MYC (29-31.8%) in DLBCL(29, 30). Once 
identified, these genetic alterations provide promising targets for the 
development of new therapeutics.  
In addition to the cell of origin classification of DLBCL subtypes 
described above, Monti and colleagues independently identified subsets 
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classified as consensus clusters based on gene clustering(31). The three 
consensus clusters are OxPhos (related to oxidative phosphorylation), 
BCR/proliferation (related to cell cycle and B cell receptor (BCR) signaling 
cascade), and HR (related to immunological host response) (31). These 
consensus clusters do not significantly overlap with the cell of origin 
classification, and are not as effective as the cell of origin classification at 
predicting response to current standard therapeutics(31), which may be why 
the cell of origin has been more widely adopted. However, the consensus 
clustering classification strategy may identify tumors that would respond well 
to other therapies, for example OxPhos tumors may be sensitive to 
proteasome inhibition and HR tumors may respond well to immune 
modulators(31). 
Germinal Centers 
B cells initially differentiate from common lymphoid progenitors into 
early stages of development in the bone marrow. During this differentiation 
process progenitor B cells (pro-B cells) undergo variable-distal-joining (V(D)J) 
recombination in order to produce a variety of immunoglobulin molecules with 
affinity for different antigens. This process provides an initial step to diversify 
the antigens recognized by B cells. With further differentiation naïve, mature, 
B cells enter the peripheral lymphoid system(32). These naïve B cells can 
become activated to enter germinal centers (GCs). 
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GCs are sites in secondary lymphoid organs (such as the spleen) 
where affinity maturation of antibodies occurs(33). Upon encountering 
antigen, naïve B cells interact with T follicular helper (TFH) cells and become 
activated to form distinct GCs within the lymphoid follicles(33–35). A recent 
paper from Tas and colleagues showed that GCs can be originally seeded by 
tens to hundreds of B cell clones, and that some of these initial clones are 
shared between neighboring GCs(36). They additionally went on to 
demonstrate that as the GC reaction progresses, many, but not all, GCs 
become dominated by descendants of a single clone(36).  
GC B cells undergo two distinct processes in order to produce high 
affinity antibodies with varying effector functions: somatic hyper mutation 
(SHM) and class switch recombination (CSR). Both processes require 
activation-induced cytidine deaminase (AID) (37). SHM is the process by 
which point mutations are induced in the immunoglobulin (Ig) gene in order to 
introduce diversity in the variable region to drive the development of high 
affinity antibodies. Mutations in the GC are induced at a high rate, about 1 
mutation in 1000 base pairs per division(37). AID deaminates deoxycytidine, 
which, depending on the repair mechanism utilized, can lead to the induction 
of mutations. The common repair mechanisms used in response to AID 
deamination are base excision repair and mismatch repair(38). These repair 
mechanisms can lead to single strand breaks or, when single strand breaks 
are in close proximity, double strand breaks. Single strand breaks can be 
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repaired by error-prone polymerases, which leads to the induction of 
mutations. Double strand breaks in the switch region of Ig lead to non-
homologous end joining, resulting in CSR(38). AID is required for affinity 
maturation and CSR. Mouse models of AID deletion are unable to undergo 
SHM or CSR(37). 
In addition to targeting the Ig gene locus, AID has been shown to affect 
more than 45% of genes expressed in GC B cells[ERROR]. This “off-targeting” of 
AID is believed to contribute to mutations that lead to B cell lymphoma. 
Understanding why some genes are targets of AID and others are not has 
been of interest. Recently, Duke and colleagues have shown that AID 
targeting in non-Ig genes appears to be based on the location of three binding 
motifs: E-box motifs, C/EBP-β motifs, and YY1 binding motifs(39). Binding 
sites for YY1, a transcription factor discussed in detail below, are enriched at 
promoter regions of highly mutated genes. Sites of the three binding motifs 
tend to co-localize in regions of highly mutated genes(39).  
Fluorescent activated cell sorting (FACS) or immunohistochemistry 
(IHC) staining for cell surface markers CD95/Fas, GL7, or peanut agglutinin 
(PNA) allows for detection of committed GC B cells as early as 4 days after 
antigen encounter. By day 7 after antigen encounter, the GCs have begun to 
polarize into dark (DZ) and light zones (LZ). In the DZ, cells undergo rapid 
proliferation and SHM of the variable regions of the Ig genes. GC B cells then 
physically transit from the DZ into the LZ where they interact with TFH cells 
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and undergo selection for high-affinity antibodies as well as CSR(35, 40–43) 
to allow for fine-tuning of Ig effector functions. CSR is not restricted to the GC: 
some evidence suggests that CSR may occur in extrafollicular regions(44, 
45).  
Although DZ and LZ have apparently different functions in the GC, they 
do not appear to be definitively separate differentiation stages, as was once 
believed(46). Gene expression profiling experiments have identified unique 
gene signatures in mouse and human DZ and LZ cells that diverge in only a 
relatively small set of genes(46). In particular, the LZ signature is dominated 
by upregulation of signatures related to CD40 signaling, NF-κB, c-Myc, and 
the negative regulation of apoptosis. The DZ signature is primarily related to 
cell cycle progression and mitosis genes(46). These dominant signatures are 
unsurprising given the demonstrated dominance of LZ cells in selection and 
DZ cells in rapid proliferation.  
Recent evidence has suggested that loss of factors essential for the 
polarity of the DZ and LZ, such as FOXO1(47, 48), do not completely 
eliminate the components of the DZ signature. Although FOXO1-negative GC 
B cells result in the loss of follicular dendritic cell polarity and instead have a 
diffuse follicular dendritic cell pattern in the GC, the FOXO-1-negative GCs 
are otherwise normal in size and number(47, 48). The loss of surface DZ 
markers is accompanied by an overall gene signature more similar to the LZ, 
however these ‘LZ only’ GCs still maintain rapid proliferation and SHM, 
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although at somewhat diminished levels compared with a normal GC(47, 48). 
This suggests plasticity in the DZ and LZ signatures, which provides a 
productive, although suboptimal due to decreased affinity maturation and 
CSR, GC response even in the absence of factors important for the DZ 
program.  
Recent studies have begun to focus more on the process of selection 
that occurs in the LZ. Although the process by which GC B cells with auto-
reactive antibodies are selected against is not fully understood, the 
mechanism for positive selection of GC B cells with increasingly high affinity 
antibodies has become more clear. Zhang and colleagues showed that 
antibodies from early plasma cells, which form and begin secreting antibodies 
prior to the formation of the GC, play an important role in ensuring the 
antibodies produced by GC B cells have progressively higher affinity for 
antigen(49). Antibodies secreted by plasma cells bind to and mask antigen 
presented by the follicular dendritic cells in the GC. If a GC B cell produces a 
higher affinity surface Ig, they will outcompete the masking antibody for 
access to the antigen. This continues to occur in the GC with progressively 
higher affinity antibodies that are produced from plasma cells as they exit the 
GC into circulation. This ensures that the highest affinity antibodies are 
produced(49).  
Additionally, Gitlin and colleagues have shown that TFH cells are 
important in the GC B cell selection process(50). As GC B cells transit from 
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the DZ to the LZ they capture and present antigen to TFH cells, which then 
signal back to the GC B cells to provide pro-survival signals. Gitlin and 
colleagues also showed that the amount of antigen presented to the TFH cells 
alters the GC B cell fate as they recirculate back into the DZ(50). GC B cells 
that capture and present a high level of antigen, suggesting a high affinity 
antibody, receive signals to increase the number of cell divisions initiated in 
the DZ. These cells with increased cell divisions consequently have increased 
somatic mutations, resulting in a higher likelihood of producing an even higher 
affinity antibody(50). GC B cells that express Ig with high-affinity for antigen 
are positively selected and differentiate into memory B cells or plasma cells to 
produce high-affinity antibodies. 
A distinct gene expression signature distinguishes GC B cells from 
other B cell subsets at different developmental stages(51–53), suggesting 
specific transcriptional programs likely play an important role in GC 
development. C-MYC is an interesting protein with a role in the GC that is 
discussed in detail below. 
One of the most important factors in the GC transcription program is 
BCL6. BCL6 is a DNA binding transcriptional repressor with a specific binding 
motif that recruits co-repressors including N-COR1, SMRT, BCOR, MTA3, 
and CTBP1(54). BCL6 can also interact with MIZ1 allowing it to bind and 
suppress expression of other genes including CDKN1A(55). It is expressed 
primarily in GC B cells and has been well characterized as an essential 
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transcription factor regulating the GC. BCL6 is required for the GC reaction 
but must be down regulated in order for cells to exit the GC as plasma cells.  
The regulation of BCL6 is tightly controlled in the GC by different 
signaling pathways. IRF8 can contribute to BCL6 activation(56), while IRF4 
transcriptionally represses Bcl6 downstream of CD40 signaling in the LZ in 
mouse experiments. In addition, BCL6 protein is regulated by acetylation of 
the PEST domains, phosphorylation leading to ubiquitination and 
degradation, and auto-inhibition by intra-molecular binding(54). Additionally, 
activation of signaling in cells with high affinity BCRs leads to degradation of 
BCL6 and differentiation(54). The primary function of BCL6 is to repress or 
prevent premature activation of GC cells by repressing members of 
BCR/CD40 signaling, repressing differentiation genes, such as Prdm1 and 
Irf4, and with modulating chemokine and cytokine responses(54). Importantly, 
BCL6 also inhibits the DNA damage response by inhibiting p53 expression, 
preventing apoptosis due to DNA damage(57).  
BLIMP-1, which can function both as a repressor of Bcl6, and is itself 
repressed by BCL6, is required for plasma cell differentiation and is highly 
expressed in plasma cells. BLIMP-1 inhibits both Bcl6 and c-Myc in order to 
maintain plasma cells in a terminally differentiated and non-proliferative 
state(58). Additionally, BLIMP-1 has been implicated as a tumor suppressor 
in DLBCL, likely due to its ability to enforce terminal differentiation(14, 16).  
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IRF4, which is also required for plasma cells and for Bcl6 expression, 
has important roles in the GC(59, 60). IRF4 is required for CSR in in vitro 
stimulated B cells 57 , and is required for GC formation by both GC B cells(61) 
and TFH cells(62). IRF4 seems to be required for early initiation of GC B cells, 
but not for their maintenance(60). IRF4 provides an example of the complex 
multitude of roles some factors play in the GC reaction, highlighting the 
difficulty in determining all the precise roles for some factors.  
Apoptosis plays an important role in regulation of GCs because the 
balance between apoptosis and survival must be carefully maintained to 
produce high affinity antibodies while preventing the development of self-
reactive antibodies. Vikstrom and colleagues showed that Bcl-xL, Bim, and 
Mcl1 are all pro-survival factors upregulated in the GC(63). They showed that 
while Bcl-xL is dispensable for the GC reaction, Mcl1 is required for formation 
of the GC. Mcl1 appears to have a dose-dependent effect on survival of GC B 
cells, as mice with one intact allele of Mcl1 display an intermediate 
phenotype, of about 50% decrease in GC B cells(63). Finally, Vikstrom and 
colleagues showed that Mcl1 is required both for activation and persistence of 
the GC(63). Further studies have shown that Mcl1 is also required for 
maintenance of plasma cells(64) and loss of one Mcl1 allele can inhibit 
lymphomagenesis(65). This highlights the importance of Mcl1 to promote 
survival of GC, plasma cells, and transformed lymphoma cells. In addition to 
the essential role for Mcl1 in pro-survival, EAF2, an activator of apoptosis in 
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cancer cells, has also been implicated as important to promote apoptosis in 
GC B cells. Loss of EAF2 in mouse GC B cells results in enlarged GCs, 
increased antibody production, and autoimmune symptoms(66). This 
emphasizes the importance of tightly controlled apoptosis in GC B cells. 
BCR and NF-κB signaling are two signaling processes that play only a 
small role in the GC. Both signaling pathways only appear to be active in a 
subpopulation of LZ GC B cells(67, 68). In the case of BCR signaling, Khalil 
and colleagues have shown that although BCR stimulation does occur in GC 
B cells, the downstream signaling cascade is prevented by high phosphatase 
activity(69). Canonical NF-κB signaling, which is associated with cell growth 
and survival, is active in a subset of LZ GC B cells as indicated by 
translocation of RELA, C-REL, and p50 into the nucleus(68). Further, Heise 
and colleagues have shown that c-REL is required for maintenance of the 
GC, while RELA is dispensable for GC and affinity maturation, but required 
for plasma cells(70). This suggests that both BCR and NF-κB signaling may 
have a role in the selection that occurs in the LZ. 
GC and DLBCL 
In addition to its essential function in adaptive immunity, the GC 
reaction plays a critical role in B-cell lymphomagenesis. Both SHM and CSR 
involve error-prone DNA repair that can target genes other than Ig in GC B 
cells(71–77), leading to genetic alterations that promote tumorigenesis. 
Furthermore, GC B cells in DZ are among the fastest dividing mammalian 
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cells with an estimated cell cycle time of 6-12 hours(78–80). Accelerated 
proliferation of GC B cells is accompanied by attenuation of DNA damage 
sensing and replication checkpoints(55, 57, 81, 82), thus increasing the risk of 
accumulation of oncogenic mutations. Because of the high proliferation rate 
and high activity of mutagenic processes in GC B cells, it is not surprising that 
most Non-Hodgkin’s lymphomas (NHLs) are derived from GC B cells or B 
cells that have passed through GCs(83–87).  
C-MYC 
 
Overview 
c-Myc is a potent oncogene; it was first discovered as the cellular 
homolog to the viral v-Myc(88, 89), was further identified in both animal and 
human tumors, and was also shown to be essential for normal mouse 
embryonic development(88). Additionally C-MYC is one of four factors 
required to reprogram fibroblasts into induced pluripotent stem cells(90). C-
MYC is a basic helix-loop-helix leucine zipper transcription factor that 
dimerizes with MAX to bind DNA. C-MYC can act to both activate and repress 
the transcription of targets, and it has been suggested that C-MYC may 
repress some targets by binding MIZ-1 and displacing the normal activating 
co-factors to mediate repression(90). C-MYC has been suggested to regulate 
at least 15% of the genome and is involved in diverse processes including cell 
cycle progression, ribosome biogenesis, signal transduction, vesicle 
trafficking, metabolism, protein folding, apoptosis, nuclear regulatory factors, 
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and DNA repair(91). However, some recent reports have indicated that C-
MYC may play a role more as an amplifier of transcriptional signals already 
present in the cell, rather than as a determinant of transcription(92). 
Regardless of how exactly C-MYC exerts its effects on transcription, it has 
been well documented to be important in many cell contexts for cell cycle 
progression(93). Interestingly, one exception was the low level of c-Myc 
detected in GC B cells. GC B cells are considered one of the most 
proliferative somatic cells, making the lack of c-Myc expression surprising 
given its role in other proliferating cell types.  
However, two groups recently utilized a c-Myc-GFP reporter system to 
identify a subset of Germinal Center B cells that do express c-Myc(94, 95). 
They reported that c-Myc has a biphasic expression pattern, being first 
expressed transiently in the early GC cells and then repressed by BCL6 in the 
highly proliferative DZ, only to be then expressed again after being selected 
for re-entry into the dark zone(94, 95). In addition, they showed that loss of c-
Myc results is loss of the GC, indicating that, although only transiently 
expressed, c-Myc is required for GC formation and maintenance(94, 95). 
 
In lymphoma 
C-MYC is a common driver of carcinogenesis in many types of 
hematopoietic malignancies. Translocation of C-MYC, leading to increased 
expression, to the highly expressed Ig loci, most commonly the heavy chain 
14
(IgH), is characteristic of Burkitt’s lymphoma, which arises from GC B 
cells(90). C-MYC translocations to Ig loci have also been documented in 
multiple myeloma, which is a malignancy of plasma B cells(96). In DLBCL C-
MYC is translocated in 8.8%-11% of cases. C-MYC has increased expression 
in 29-38.1% of DLBCL cases(29, 30), demonstrating the importance of C-
MYC in DLBCL. Clinically, an increase in C-MYC, whether through 
translocation, amplification, or other methods, is an adverse prognostic factor 
for DLBCL(29). Currently the treatment of C-MYC-high DLBCL is an unmet 
medical need.  
 
Therapeutic inhibition 
Historically, transcription factors have been considered to be 
‘untargetable’ by small molecule inhibition, which is why many small 
molecule-targeting strategies focus on upstream factors such as kinase 
inhibition. However, treatment focused on transcription factor oncogenes, 
such as C-MYC, would provide an ideal treatment against many types of 
cancer, regardless of the upstream pathways that lead to C-MYC activation. 
This has led to many strategies to attempt to attenuate c-Myc expression and 
eliminate tumors that are addicted to C-MYC.  
One strategy has been to target the dimer C-MYC-MAX. C-MYC dimerizes 
with MAX to bind DNA, so inhibition strategies have focused on both limiting 
the dimerization event itself, as well as inhibiting its subsequent binding to 
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DNA. Two inhibitors stand out in these regards. 10058-F4 is an inhibitor of C-
MYC-MAX dimerization and has been shown effective in many in vitro cell 
line experiments(90) as well as in vivo against N-MYC driven tumors(97). The 
other inhibitors, Celastrol and celastrol-inspired molecules, inhibit the C-MYC-
MAX dimer from binding to DNA(98). Efficacy of these molecules has been 
shown across various cell lines in vitro.  
Another strategy to inhibit C-MYC-addicted tumors targets effector 
molecules downstream of C-MYC. This strategy has been shown effective in 
certain situations, but is complex due to differences in downstream C-MYC 
target molecules depending on the cellular and oncogenic context. Many of 
these strategies have been proof-of-principle in nature, utilizing shRNA, which 
are not currently amenable to clinical applications. Some of the effective 
downstream targeting strategies have included shRNA or small molecule 
inhibition of some metabolic downstream effectors including ornithine 
decarboxylase (ODC), lactate dehydrogenase A (LDHA), and glutaminase 
(GLS) (90). These metabolic targets were chosen because of their 
importance downstream of C-MYC in certain tumor contexts. 
Additional studies aiming to inhibit C-MYC activity have focused on 
modulating the effects of C-MYC on microRNA expression, specifically by 
adeno-associated viral expression of miR-26a in a C-MYC-induced model of 
liver cancer. miR-26a is repressed by C-MYC and the reintroduction of miR-
26a in the liver cancer model proved efficacious by reducing the size of liver 
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tumors(99). These types of inhibition of C-MYC-targets may be effective in 
some contexts, but not in others. Although C-MYC aberration is common in 
up to 70% of human tumors, the important downstream functions may vary 
widely. 
This thesis focuses on the inhibition of C-MYC expression and activity 
directly through the use of the small molecule bromodomain and extra 
terminal domain (BET) family inhibitor JQ1(100). JQ1 competitively interacts 
with BET bromodomains, thus preventing them from binding to chromatin. 
BET bromodomains are scaffolding factors that recognize acetylated lysines 
on chromatin and facilitate transcriptional activation. The four BET 
bromodomains for which JQ1 has high affinity are BRD4, which JQ1 has the 
highest affinity for, BRD2, BRD3, and BRDT. JQ1 was originally developed 
for use in NUT (nuclear protein in testis)-midline carcinoma, in which BRD4 is 
translocated(100). Further studies identified inhibition of BET bromodomains 
as a potential method to inhibit C-MYC transcriptional activity. C-MYC 
mediated transcription is associated with acetylated lysines on chromatin and 
is also involved in pause release of RNA polymerase II, similarly to BRD4. 
These findings prompted Delmore and colleagues to investigate the utility of 
JQ1 in inhibition of C-MYC transcription(101). They found that not only was 
C-MYC-mediated transcription inhibited, but also the transcription of C-MYC 
itself was inhibited by JQ1. This finding was validated in a number of studies 
primarily focused on hematopoietic malignancies, including multiple myeloma, 
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acute myeloid leukemia, promyelocytic leukemia, B-cell acute lymphoblastic 
leukemia, and Burkitt’s lymphoma, where C-MYC has a well-established role 
as a dominant oncogenic driver(102–107).  
These studies began to establish JQ1 as an indirect inhibitor of C-
MYC, however further investigation, particularly in some solid tumors, 
suggested that JQ1 could have anti-tumor effects independently of C-MYC 
inhibition(108, 109). Further studies suggest that BRD4 associates with 
enhancers and super enhancers in cancer to promote high levels of 
transcription from a small set of essential genes(106). Lovén and colleagues 
proposed that JQ1-mediated inhibition of BRD4 preferentially decreases 
expression of oncogenes that have been highly selected for in any specific 
cancer(106). This may provide an explanation for the broad efficacy seen for 
JQ1 inhibition across tumor types. BRD4 may be loaded preferentially at the 
highly expressed oncogenes to which a given tumor is addicted and when this 
association is disrupted, the cell survival rapidly deteriorates. A study from 
Chapuy and colleagues revealed highly asymmetric loading of BRD4 at 
super-enhancers in DLBCL cells. These super-enhancers and genes that 
they regulate are particularly sensitive to JQ1 inhibition, explaining the 
selective effect of JQ1 on oncogenic and lineage-specific transcriptional 
circuits(110).  
 
18
Yin Yang 1 
Yin Yang 1 (YY1) has been implicated in the GC transcriptional 
program. Additionally, high expression of YY1 is an indicator for poor 
prognosis in DLBCL. 
 
The multi-functional protein 
YY1 is a multi-functional protein with roles in many types of cellular 
processes including transcriptional activation and repression, X-chromosome 
inactivation, contraction of DNA loci(111), protein stability(112), viral gene 
expression, epigenetic regulation, and oncogenesis(113). YY1, a GLI-Kruppel 
class protein, has four zinc fingers that allow it to directly bind to and interact 
with DNA. It also has a REPO domain which allows YY1 to bind polycomb 
repressive complex (PRC) members, specifically YAF2(114). The core PRC 
has no components with DNA binding capabilities, which raises questions 
about how PRC is targeted to various DNA loci. It has been proposed that 
YY1 may act to target PRC via its DNA binding zinc finger domains(114). The 
carboxyl terminus region of YY1 physically interacts with other proteins 
important in transcription, including EP300, C-MYC, and HDAC2(113).  
Loss of YY1 causes embryonic lethality in a dose dependent 
manner(115, 116). YY1 is also involved in differentiation of muscle, intestinal 
stem cell self-renewal(117), and cell growth in many cell types(113). Schug 
and colleagues have suggested that YY1 could regulate as much as 10% of 
the total human genome, likely in a cell-dependent context(118). In order to 
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classify some of the YY1 targets, Affar and colleagues utilized a mouse model 
in which YY1 levels in mouse embryonic fibroblasts (MEFs) are decreased to 
25% of normal expression(115).  Microarray on these MEFs reveal changes 
in many genes which are primarily due to the decrease in YY1, although does 
not identify those which may be indirect versus direct YY1 targets. 
Nonetheless, this study indicates that YY1 has a role in regulation of cell 
cycle genes, such as CDKN1A (p21), mitosis and cytokinesis genes 
(including kinesin family members and aurora kinases), DNA replication and 
repair genes (including polymerases, RAD18, and Ung), apoptosis related 
genes (such as Bcl-xL and FAS), cell growth and proliferation genes (such as 
Btg2, Fos, and Src), and developmental genes (including BMPs and myosins) 
(115). Further studies have identified other, direct, transcriptional targets of 
YY1 including activation of c-Myc(119, 120) and Xist(121).  
YY1 ChIP-Seq has been performed in a number of human cell 
lines(122). GM12878, a human B lymphocyte cell line, has YY1 binding peaks 
associated with 719 unique genes. By comparing these YY1 peaks to those in 
two other human cell lines (NT2-D1 and K562), I found that 50% (360/719) of 
genes with YY1 binding in GM12878 also have YY1 binding in the other two 
cell lines. Gene ontology analysis of these common targets shows enrichment 
for maintenance processes, including RNA metabolic processes, nucleobase-
containing compound metabolic processes, and cellular component 
biogenesis. This suggests that, in the context of human B cells, at least half of 
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YY1 targets may be specific to the cell type, while the remaining targets 
involve common biological processes.  
In addition to YY1’s role in transcriptional activation and repression, it 
appears that the protein has other non-transcriptional roles. In particular, YY1 
has been shown to disrupt p53-EP300 protein interaction by blocking EP300-
dependent acetylation and stabilization of p53. YY1 also interacts with MDM2 
to promote p53-MDM2 complex, which leads to increased p53 
degradation(123). This interaction of YY1 with MDM2 to enhance MDM2-p53 
binding can be disrupted by p14ARF(124). YY1 can also act to alter protein 
localization, as in the case of AID protein. Zaprazna and Atchison showed 
that YY1 and AID proteins physically interact and that YY1 increases the 
nuclear AID levels in activated B cells by increasing AID protein stability(112). 
These studies provide examples in which YY1 alters protein-protein 
interactions or protein stability leading to post-translational regulation of 
protein levels. 
 
In B-cells 
Interest in the role of YY1 in B cells began when YY1 binding sites 
were discovered in enhancers important for variable-distal-joining (V(D)J) 
recombination(111). This led to the development of a conditional YY1 allele in 
mice to allow tissue specific deletion in order to bypass the embryonic 
lethality of knockout mice. Ablation of YY1 in early B cells using Mb1-cre 
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blocks the transition from progenitor B cells to precursor B cells partially 
through impairing chromatin contraction at the Ig heavy chain locus and V(D)J 
recombination(111). Pan and colleagues found that the YY1 REPO domain, 
which is required for involvement in PRC, is necessary for progenitor to 
precursor B cell transition(125). Additionally, they have shown that YY1 
without the REPO domain impairs Ig kappa chain rearrangement, but not Ig 
heavy chain, suggesting that YY1 may function to recruit PRC in Ig kappa 
rearrangement but not for Ig heavy chains(125). YY1 appears to require tight 
regulation in normal B cell development. When YY1 is overexpressed in wild 
type bone marrow, normal B cell development is impaired, resulting in fewer 
B lineage cells, while myeloid lineages remain normal(126). Together this 
evidence suggests that YY1 levels must be carefully controlled for normal B 
cell development. 
Recently, binding motifs for YY1 were found to be significantly 
enriched in the promoter regions of genes preferentially expressed in GC B 
cells, suggesting that YY1 functions as a master regulator of the GC 
reaction(51). However, experimental evidence supporting a role for YY1 in the 
GC is lacking. One group attempted to define the role of YY1 in the GC by 
investigating the loss of YY1 in B cells stimulated in vitro(112). They showed 
that YY1 controls CSR and levels of nuclear AID, but does not effect 
proliferation in vitro(112). Although this provides some suggestion that YY1 
has a role in the GC, current in vitro models do not represent the vast 
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complexity of an in vivo GC reaction. During the preparation of this thesis a 
study was published demonstrating that loss of YY1 can diminish the GC 
response in mice(127). 
 
In cancer 
YY1 has been implicated as a potential oncogene. A review from 
Bonavida and Kaufhold(128) provides an overview of YY1 expression in 
various types of cancer. They indicate many cancer types including bladder, 
brain, breast, colon, gastic, hepatocellular carcinoma, cervical, ovarian, and 
prostate cancer display increased YY1 expression compared with normal 
tissue. Interestingly, although YY1 expression is increased in pancreatic 
ductal adenocarcinoma, it appears that YY1 suppresses invasion and 
metastasis, meaning increased YY1 correlates with better outcome. In 
esophageal cancer, YY1 is down regulated compared with normal tissue, 
which is in contrast to all of the other cancer types surveyed(128).  
YY1 has also been implicated in lymphoma. YY1 is significantly 
increased in human DLBCL, Burkitt’s lymphoma, and follicular lymphoma 
compared with reactive lymph nodes or normal B cells(129–131). Further, 
high levels of YY1 expression correlates with a worse survival prognosis in 
human DLBCL and follicular lymphoma patients(130, 131).  
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SMURF2 
 Smad ubiquitin regulatory factor 2 (SMURF2) is a tumor suppressor. In 
DLBCL low Smurf2 expression is a poor prognostic indicator. 
 
The E3-ubiquitin-ligase 
SMURF2 is a Nedd4 family E3-ubiquitin ligase(132) containing an 
amino-terminal C2 domain, two WW domains, which facilitate protein-protein 
interactions with PPXY motifs, and a carboxyl-terminal HECT domain which 
ubiquitinates the target(133). SMURF2 was originally identified for its ability to 
ubiquitinate and degrade members of the TGF-β family including SMAD1. 
Subsequent studies have shown that SMURF2 can ubiquitinate and mediate 
the degradation of multiple other factors including SMURF1(134), YY1(135, 
136), ID1(137), ID3(137), RNF20(138), RUNX2(139), RAP1B(140), and 
components of the Wnt signaling pathway(141–143).  
 
The tumor suppressor and aging factor 
SMURF2 has been identified as a tumor suppressor in a number of 
different types of cancer including lymphoma(138, 144), hepatocellular 
carcinoma(138, 144), breast cancer(134), and melanoma(144). Multiple 
groups have shown that loss of Smurf2 in mice results in increased cancer 
incidence with a long latency(138, 144). In addition low SMURF2 expression 
in human lymphoma patients is predictive for poor prognosis(135). Ectopic 
expression of wild type SMURF2 significantly decreases the growth of human 
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DLBCL cell lines in a E3-ubiquitin-ligase dependent manner. When the 
catalytic cysteine residue is mutated and this mutant is overexpressed there 
are no changes to proliferation, suggesting SMURF2 requires E3-ubiqutin-
ligase activity to function as a tumor suppressor(135). 
In addition to its role as a tumor suppressor, SMURF2 has been 
implicated as an aging factor. Loss of Smurf2 results in increased number of 
hematopoietic stem cells (HSC) in both young and old mice, and in more 
functional HSCs(145). HSCs from old mice, although more numerous, are 
less able to repopulate the blood lineages and are more likely to exhaust. 
Through serial transplantation and competitive repopulation, Smurf2-deficent 
HSCs from both young and old mice are less likely to exhaust and are better 
able to compete with young wild type HSCs than either young or old wild type 
HSCs(145). This shows that SMURF2 is an aging factor, which when 
decreased, provides anti-aging properties. 
The implication of SMURF2 as protective in cancer, but detrimental to 
stem cell aging, highlights the often dichotomous nature of human aging. In 
order to maximize the healthy reproductive years, the human body is 
programed to prevent cancer, which, as exemplified by SMURF2, can later 
have detrimental effects on the aging process. How SMURF2 is acting 
dichotomously can help advance the understanding of the underlying biology 
of cancer and aging and create therapies that modulate SMURF2 to promote 
healthy HSCs and healthy aging or inhibit cancer. 
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SMURF2 has an important role in regulating senescence, by mediating 
the degradation of ID1, which in turn results in an increase in p16 levels(137). 
P16 is a well-characterized senescence factor as part of the p16-RB pathway. 
When SMURF2 is ectopically expressed in human fibroblasts, p16 levels are 
increased and early senescence occurs(137). It has also been shown that 
Smurf2-deficent MEFs continue to proliferate long after wild type MEFs have 
senesced and that loss of Smurf2 appears to promote immortalization of 
MEFs(144). Although there is a well-established role for SMURF2 in 
senescence, it is less clear if the regulation of senescence is what provides 
SMURF2 with tumor suppressor and aging properties.  
The role of senescence in cancer is well documented, beginning with 
the concept of oncogene-induced senescence, which was first explored by 
Serrano and colleagues. They showed that oncogenic RAS expression 
promotes premature senescence in otherwise normal cells(146). This has 
subsequently been explored with additional oncogenes and tumor 
suppressors including B-RAF over expression(147), and PTEN loss(148). An 
example of oncogene-induced senescence occurring naturally in vivo is in the 
context of benign skin nevi (commonly referred to as skin moles). These 
abnormal melanocyte growth lesions typically harbor oncogenic mutations 
including B-RAF and N-RAS, however they often do not progress to 
malignant melanoma, or if they do progression has a very long latency(149, 
150). These nevi have been shown to display markers of senescence, 
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providing an in vivo example of oncogene-induced senescence as a 
preventative measure in tumorigenesis. The rare nevi that progress to 
malignant melanoma typically have additional pathway mutations that 
circumvent the senescence pathway. In addition to the role senescence has 
in prevention of malignancy, it can also occur as a response to treatment in 
full malignancy, termed therapy-induced senescence. Schmitt and colleagues 
showed that tumor-bearing mice with therapy (or drug) induced senescence 
have a better outcome than those with senescence defects(151). This 
solidifies an important role for senescence in cancer prevention and 
treatment. 
 Ramkumar and colleagues have suggested that SMURF2 tumor 
suppressive activity is likely due to the decrease of senescence in the mouse 
tissues(144), however Blank and colleagues have suggested an alternative 
scenario that is also possible(138). They suggest that SMURF2 acts to 
promote genomic stability by targeting RNF20, an epigenetic modifier, for 
degradation(138). It seems most likely that in the context of tumor 
suppression, both control of genomic stability and promotion of senescence 
could likely be important. 
 
SMURF2-YY1-C-MYC Axis 
Previous studies(135, 136) have shown that SMURF2 mediates the 
ubiquitination and degradation of YY1.  Any decrease in YY1, as a multi-
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functional protein with many roles, likely results in a multitude of molecular 
changes in the cell, which may have broad reaching effects. In previous 
studies it has been shown that when SMURF2 mediates the degradation of 
YY1, a similar decrease in the mRNA and protein of the transcription factor C-
MYC is observed. C-MYC has many diverse roles in the cell, however, in the 
context of many types of cancer, C-MYC has been well characterized as an 
oncogene with roles in proliferation, altering cell metabolism(88), and 
differentiation(152).  This SMURF2-YY1-C-MYC axis therefore constitutes a 
potentially important pathway in the development and maintenance of cancer. 
The previous study(135, 144) showed that a decrease in Smurf2 levels leads 
to increased incidence of cancer, primarily B cell lymphoma. Decreased 
SMURF2 protein expression in patient samples has been shown to be 
predictive of a poor clinical outcome in patients treated with the standard of 
care, R-CHOP.  
DLBCL tumors with high C-MYC expression constitute an unmet 
clinical need. As detailed above, the small molecule inhibitor JQ1 can 
indirectly inhibit C-MYC activity, making it an intriguing candidate for use in 
high C-MYC expressing tumors. This thesis will examine the hypothesis that 
JQ1 is an effective treatment for human DLBCL. Some DLBCL tumors have 
amplification or translocation of C-MYC, which causes the increased C-MYC 
protein. However, many of the tumors with high C-MYC expression do not 
have a clear mechanism for the increase. Understanding the underlying 
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mechanism of increased C-MYC expression may provide additional 
therapeutic targeting opportunities.  
One possibility is that C-MYC is controlled at the transcriptional level. 
YY1 has been shown to activate C-MYC transcription. Previously, it has been 
shown that knockdown of YY1 in human DLBCL cell lines leads to a decrease 
in cell number(135). High YY1 expression is correlated with poor survival 
prognosis in lymphoma. In addition, YY1 has been suggested to be a master 
regulator of the GC transcriptional program(51). As discussed above, GC or 
post-GC cells are the cell-of-origin for most DLBCL, and perturbations in the 
GC may contribute to DLBCL development. This led me to investigate if YY1 
regulates the GC, and test the hypothesis that YY1 is essential for the GC 
reaction.  
Previous work established SMURF2 as an important regulator of YY1 
protein stability. In this thesis I show that YY1 protein is increased in the GC 
(Figure 3.1). As detailed above, SMURF2 has been established as a tumor 
suppressor in B cell lymphoma. This led me to hypothesize that decreasing 
SMURF2 in the GC would perturb the GC reaction, potentially providing a 
mechanism for the tumor suppressive activity of SMURF2. The goal of this 
thesis is to further the understanding of this SMURF2-YY1-C-MYC pathway 
so that this knowledge may be used to advance the lymphoma field and 
inform treatment progression. 
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CHAPTER II: Inhibition of bromodomain proteins for 
the treatment of human diffuse large B cell lymphoma 
 
JQ1 is a small molecule inhibitor of the bromodomain and extra-terminal 
(BET) family of bromodomain proteins. Studies have found anti-proliferative 
and pro-apoptotic effects of JQ1 in several types of malignancies. In some 
hematopoietic malignancies, this effect has been linked to inhibition of C-
MYC. This led me to hypothesize that JQ1 treatment in DLBCL cells would 
result in decreased cell proliferation and viability in a C-MYC-dependent 
manner. 
Results 
Human DLBCL cells are sensitive to JQ1 
Recent studies found anti-proliferative and pro-apoptotic effects of 
JQ1, particularly in hematopoietic malignancies, and these effects of JQ1 are 
primarily mediated through inhibition of c-MYC(100–102, 104, 105, 107, 109, 
153, 154). Given the recently reported incidence of c-MYC overexpression in 
DLBCL(29), I hypothesized that JQ1 would inhibit human DLBCL cell 
proliferation and therefore might be effective in DLBCL therapy. To test this 
hypothesis, I used a panel of 11 human DLBCL cell lines, including four cell 
lines classified as the ABC subtype [HLY-1(155), HBL-1(18), OCI-Ly3 and 
OCI-Ly10(156)] and seven cell lines classified as the GCB subtype [SU-DHL-




34
and 7.8% for 500 nM JQ1-treated compared to 0.7% for DMSO-treated 
control) and SU-DHL-10 (3.1% for 250 nM JQ1-treated and 3.5% for 500 nM 
JQ1-treated compared to 1.1% for DMSO-treated control) (Figure 2.3).   
In comparison, doxorubicin treatment led to a significant increase in 
the sub-G1 population in SU-DHL-10, OCI-Ly3 and OCI-Ly8 cells after just 2 
days of treatment (Figure 2.2 and 2.3).  
Neither doxorubicin nor JQ1 induced a significant increase in the sub-
G1 population in SU-DHL-4 cells up to 4 days of treatment (Figure 2.3). To 
further investigate cell death after JQ1 treatment, I measured caspase 3/7 
activity as an indicator of apoptosis. I found a small but consistent increase in 
caspase 3/7 activity 4 days after treatment with 250 nM JQ1 compared with 
DMSO-treated control cells in OCI-Ly3 (2.8-fold increase) and SU-DHL-10 
(1.6-fold increase) cells, whereas a significant increase in caspase 3/7 activity 
was observed in both OCI-Ly3 (12.9-fold increase) and SU-DHL-10 (353-fold 
increase) cells after 4 days of doxorubicin treatment compared to DMSO-
treated controls (Figure 2.4A). 
I found that this initial G1 cell cycle arrest was followed by either 
apoptosis or senescence after prolonged (7-day) treatment with JQ1. OCI-
Ly3, SU-DHL-4 and SU-DHL-10 cells showed significant increases in the sub-
G1 populations: 27.5% (250 nM JQ1) and 12.2% (500 nM JQ1) compared to 
1.0% (DMSO) for OCI-Ly3; 19.3% (250 nM JQ1) and 31.6% (500 nM JQ1) 
compared to 2.8% (DMSO) for SU-DHL-4; 9.2% (250 nM JQ1) and 8.2% (500 


37
To further characterize the anti-proliferative effects of JQ1, I removed JQ1 
after 7 days of treatment to investigate whether removal of the drug from the 
cells for an extended period allowed the cells to re-enter the cell cycle. All of 
the four cell lines tested either maintained growth arrest, or in the case of SU-
DHL-4, had decreased cell numbers (Figure 2.5A). This suggests that JQ1 
treatment caused cells to permanently exit the cell cycle. To test whether 
these cells entered senescence, I stained them for senescence associated β-
galactosidase (SA-β-gal) activity. After 7 days of treatment with 250 nM JQ1, I 
observed a significant percentage of cells staining positively for SA-β-gal in 
OCI-Ly3 and OCI-Ly8 cells (71.6% and 90.6%, respectively). In contrast, only 
5.4% or no SA-β-gal positive cells were observed in SU-DHL-10 and SU-
DHL-4 after JQ1 treatment for 1 week (Figure 2.5B). These data indicate that 
JQ1 treatment results in two independent phenotypes in human DLBCL cell 
lines: apoptosis and senescence.  
JQ1 treatment leads to suppression of C-MYC expression  
As JQ1-mediated suppression of C-MYC expression is responsible for 
its anti-proliferative effect in various types of cancer cells(101, 103, 105, 107, 
157, 158), I examined C-MYC protein levels in the 11 DLBCL cell lines that 
were characterized for response to JQ1 treatment (Figure 2.6A). In particular, 
OCI-Ly3(159) and SU-DHL-4(160)cells have C-MYC amplifications. HBL-
1(161), OCI-Ly8, OCI-Ly18(159), SU-DHL-6, and SU-DHL-10(160) cells have 
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MYC causes apoptosis or senescence phenotype, or if C-MYC is rather 
decreased due to the decrease in proliferation. 
JQ1 treatment of xenograft tumors results in significantly decreased 
rate of tumor growth and increased survival of mice 
In order to evaluate how DLBCL cells xenografted into NSG mice 
would respond to a regimen of treatment with JQ1, I engrafted OCI-Ly8 cells 
subcutaneously into NSG mice and measured tumor volume. When at least 
one tumor on each mouse was detectable by palpation, I began a daily 
treatment of JQ1 (50 mg/kg of mouse body weight) or vehicle for 21-days. 
Seven mice from the vehicle-treated group and four mice from JQ1-treated 
group had to be euthanized before the end of treatment regimen because 
tumor volumes reached 1000 mm3. Tumor growth was significantly decreased 
in JQ1 treated mice compared with vehicle treated (P<0.001) (Figure 2.7A). In 
addition to subcutaneously injected tumors, I used OCI-Ly8 cells to engraft 
NSG mice intraperitoneally in order to better mimic human disease. Six days 
after cell injection, I began daily treatment with 50 mg/kg JQ1 or vehicle for 
21-days. After the completion of treatment, I monitored the mice until all were 
moribund and therefore had to be euthanized. JQ1 significantly (P=0.0039) 
increased survival time with a mean survival of 33.6 days compared with 29.5 
days for vehicle (Figure 2.7B). Upon sacrifice, mice displayed infiltration of 
tumor cells into spleen and liver (Figure 2.7C) as well as prominent abdominal 
masses.  Overall, these results demonstrate that treatment of DLBCL with 
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every 48 hours with fresh media to maintain the same concentrations. After a 
week of treatment, I removed JQ1 by spinning the cells at 1500 RPM for 5 
minutes and replating the cells in fresh media.  
 
Analyses of cell viability, cell cycle, and apoptosis 
To assess cell viability, cells were collected and re-suspended in staining 
media: Hanks’ balanced salt solution (Life Technologies), 3% FBS, 0.2% 
sodium azide, 1 mM EDTA and 1 µg/ml propidium iodide (PI). Viable and total 
cell numbers were determined using a MACSQuant analyzer (Miltenyi 
Biotech). For cell cycle analysis, cells were collected, re-suspended in PBS, 
permeabilized and fixed with 95% ice-cold ethanol overnight. PI was added 
before analyzing samples by flow cytometry using a FACSCalibur (BD 
biosciences). Flow cytometry data were analyzed using FlowJo software 
(Treestar). Apoptosis was analyzed using a Caspase-GLO 3/7 kit with 
GloMax-96 microplate luminometer (Promega) following manufacturer’s 
recommendation. 
 
Senescence associated β-galactosidase (SA-β-gal) staining 
Cells were collected and fixed in a fixation solution (2% formaldehyde and 
0.2% glutaraldehyde in PBS) for 5 min. After washing in PBS, cells were 
stained in SA-β-gal staining solution (40 mM citric acid/phosphate buffer, pH 
6.0, 5 mM potassium ferrocynide, 5 mM potassium ferricynide, 150 mM NaCl, 
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2 mM MgCl2, 1 mg/ml X-gal). After staining overnight at 37°C, cells were 
cytospun onto coverslips and examined by light microscopy. 
 
Western blots 
Whole cell lysates were isolated using RIPA buffer (50 mM Tris–HCl pH 7.5, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid and 
0.02% sodium azide) plus fresh protease inhibitor complete (Roche). Lysates 
were run on SDS–PAGE Criterion X-gel (Bio-Rad) and transferred to 
nitrocellulose membranes (GE Osmonics). Membranes were probed with 
antibodies against BCL-XL, Rb (Cell Signaling), C-MYC, p21, p53, GAPDH, 
β-ACTIN (Santa Cruz Biotechnology), and p16 (Abcam). Membranes were 
visualized using Western lightening chemiluminescence detection 
(PerkinElmer) and ChemiDoc MP System with Image lab software (Bio-Rad). 
 
Mouse studies  
All mouse studies were carried out according to guidelines approved by the 
Institutional Animal Care and Use Committee of University of Massachusetts 
Medical School. Male NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (2-4 
months old from Jackson Laboratory) were maintained on a bi-weekly regime 
of antibiotic water (400 µg/ml of sulfamethoxazole and 80 µg/ml of 
trimethoprim oral suspension from HiTech Pharmacal). For tumor engraftment 
studies, 5×106 cells suspended in 50% matrigel (BD Biosciences) were 
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injected subcutaneously (SC) into the hind flank of each mouse (two sites per 
mouse). Tumors were measured using a digital caliper three times weekly for 
21-days or until sacrifice. Tumor volumes were calculated using a formula: 
!!!!!!!!!, where r1-3 are the radii for three dimensions of the tumor. For survival 
studies, 5 ×106 cells were injected into mice intraperitoneally (IP). After 
detection of tumor by palpation (for SC injected) or 6 days after tumor cell 
injection (for IP injected), tumor-bearing mice were randomized and treated 
with daily IP injection of JQ1 (50 mg per kg of mouse body weight) for 21-
days or until tumor volume reached 1000 mm3 or mice became moribund. 
JQ1 was first dissolved in DMSO and subsequently mixed with 10% 
hydroxypropyl-β-cyclodextrin (Sigma) to improve solubility. Vehicle treated 
mice were injected with the equivalent volume of DMSO mixed with 10% 
hydroxypropyl-β-cyclodextrin. Tissues were harvested 2 hours after injection 
with JQ1 or vehicle in 10% neutral-buffered formalin for paraffin sections. 
Tissue sections were stained with Hematoxylin & Eosin. 
 
Statistical analyses 
Data were presented as mean ± SD. Welch’s t-test and two-way ANOVA 
were used for statistical analyses, with P<0.05 considered as statistically 
significant. Kaplan-Meier survival curves were plotted and analyzed with the 
log-rank test.  
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CHAPTER III: YY1 regulates the germinal center 
reaction by inhibiting apoptosis and maintaining dark 
zones 
Given the established connection between the GC and DLBCL, I investigated 
which molecular features may be important in the GC that are also implicated 
in DLBCL. The target of interest that I choose is YY1. YY1 is misregulated in 
DLBCL, is known to activate c-Myc transcription, and has been proposed as a 
master regulator of the GC transcription program. This led me to test the 
hypothesis that YY1 is an important regulator of the GC reaction. 
Results 
YY1 protein level is increased in GC B cells 
Despite the observation that YY1 binding motifs are significantly 
enriched in the promoter regions of genes preferentially expressed in GC B 
cells, the YY1 transcript is not changed in GC B cells compared to other B cell 
subsets(51). As the transcript level of a transcription factor is not necessarily 
an accurate indicator of its transcriptional activity, I examined the YY1 protein 
level in GC B cells. I immunized C57BL/6 wild-type mice with sheep red blood 
cells (sRBCs) to stimulate the GC reaction. At day 10 post-immunization, 
when the GC reaction is at the peak, I purified GC B cells (B220+GL7+CD95+) 
and non-GC B cells (B220+GL7-CD95-) in spleen by FACS for Western blot 
analysis. I found that YY1 protein levels were significantly increased (7.2-fold) 
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blocks the transition from progenitor B cells to precursor B cells(111). As this 
block prevents the formation of mature B cells in secondary lymphoid organs, 
the use of Mb1-Cre or CD19-Cre(165) to delete YY1 in B cells is not suitable 
to study the role of YY1 in the GC reaction.  
To ablate YY1 selectively in mature B cells or particularly in GC B 
cells, I used AID-Cre. The Aicda gene encodes activation-induced cytidine 
deaminase (AID), which is essential for SHM and CSR in GCs(37). AID 
expression is induced to high levels in GC B cells and then turned off during 
post-GC differentiation into plasma or memory B cells(166). In the AID-Cre 
mice, the Cre gene is inserted to replace exon 1 of Aicda, resulting in Cre 
expression under control of the Aicda locus and simultaneous disruption of 
Aicda(74).  AID-Cre thus mediates recombination between loxP sites in GC B 
cells, and the resulting recombined allele is carried over when GC B cells 
differentiate into memory or plasma B cells(74, 166). It has previously been 
reported that loss of one Aicda allele, as in this AID-Cre model, causes a 
slight decrease in the functionality of the GC reaction and a slight increase in 
size of GC(167), which does not appear to have an effect in our system 
(Figure 3.3E). To determine the dynamics of AID-Cre activity in GCs, I utilized 
a Cre reporter mT/mG mouse strain, in which membrane-targeted fluorescent 
protein mTomato (mT) is expressed under the control of the ROSA26 
promoter prior to Cre-mediated recombination, while mGFP (mG) is 
expressed after Cre-mediated deletion of mT(168). I crossed the AID-Cre 
51
mice with the mT/mG mice to track cells that had undergone Cre-mediated 
recombination at ROSA26 at various time points after immunization with 
sRBCs. Mice that were not immunized with sRBCs exhibited a low but 
detectable level of the GC reaction (Figure 3.3A). About 50% of GC B cells in 
unimmunized mice were GFP positive (Figure 3.3C), indicating these cells 
had undergone Cre-mediated recombination. Furthermore, the GFP+ 
population in unimmunized mice was enriched for GC B cells, whereas very 
few cells (<1%) in the GFP- population were GC B cells (Figure 3.4). These 
observations are consistent with the notion that AID is induced in GC B cells 
and AID-Cre selectively mediates recombination in GC B cells. Because of 
the low background GC reaction, unimmunized mice do not represent true 
“day 0” time points where no GC B cell is detected. After sRBC immunization, 
there was a significant increase in GC B cells (B220+GL7+CD95+) between 
day 4 and day 5 post-immunization (Figure 3.3A and 3.3E). Coinciding with 
this increase in GC B cells, I found a substantial increase in GFP+ cells, in 
particular the mG+mT+ population (Figure 3.3B). These double positive cells 
were newly recombined as mGFP was expressed but mTomato protein was 
not yet degraded. Within the GC B cell population, I found a dramatic 
increase in the newly recombined mG+mT+ cells between day 4 and day 5 
(Figure 3.3C and 3.3G), suggesting that AID-Cre is active as early as day 4 in 
GC B cells. In contrast, very few GFP+ cells were found in non-GC B cells 
(B220+CD95-GL7-) or non-B cells (B220-) (Figure 3.3D and 3.3F), suggesting 
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point that newly formed GC B cells can be reliably detected by flow cytometry 
using cell surface markers. Day 6 is a time during which GCs are still 
maturing, whereas day 10 is at the peak of the GC reaction(33–35).   
After sRBC immunization, B220+ populations remained largely 
unchanged (Figure 3.5). Starting at day 4 post-immunization, I observed a 
gradual increase in the frequency and total number of GC B cells 
(B220+CD95+GL7+) in spleens of wild type, YY1Fl/Fl, or AID-Cre control mice 
compared to unimmunized mice (Figure 3.5). However, a significant decrease 
in the frequency of GC B cells was observed in YY1CKO mice compared to 
YY1Fl/Fl, AID-Cre, or wild-type mice at day 4 (Figure 3.5A). This decrease 
resulted in 30-70% reduction of total GC B cells in the spleens of YY1CKO 
mice compared to control mice.  Significant decreases in the frequency and 
number of GC B cells in YY1CKO mice was observed at day 6 and day 10 
post-immunization (Figure 3.5B and 3.5C). Further, at day 10 post-
immunization, I found that the frequency and number of GC B cells in YY1CKO 
mice continued to decrease (by 3-fold) compared to day 6, while control mice 
had largely maintained their GC B cells (Figure 3.5C). The decrease in GC B 
cells in YY1CKO mice was similar when I used B220+PNA+ for GC B cells 
(Figure 3.6) or stained with PNA in immunohistochemistry for the presence of 
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Because there were still small numbers of GC B cells present in 
response to sRBC immunization in YY1CKO mice even at day 10 (Figure 3.5), I 
sought to determine whether these GC B cells had undergone complete 
deletion of both YY1 alleles, or whether one or both alleles of YY1 still 
remained intact. I sorted GC B cells from YY1CKO mice and used single-cell 
PCR to determine the status of the YY1 locus (Figure 3.8). At day 4 post-
immunization, 73% of GC B cells had both YY1 alleles deleted, whereas 
10.8% and 16.2% of GC B cells had only one YY1 allele deleted or no YY1 
deletion in YY1CKO mice, respectively (Table 3.1). Despite increased AID-Cre 
activity from day 4 to day 10 (Figure 3.3), the frequency of GC B cells with 
both YY1 alleles deleted did not increase at day 10 (69.6%) compared to day 
4. Furthermore, the fraction of GC B cells without YY1 deletion was similar at 
day 4 (16.2%) and day 10 (21.6%), suggesting a counter selection against 
cells with deletion in both YY1 alleles. Collectively, these data indicate that 
although YY1-null GC B cells are generated, YY1 ablation greatly reduces the 
magnitude of the GC response.  
To investigate whether YY1-null GC B cells could be identified using 
flow cytometry instead of single-cell PCR, I crossed the mT/mG reporter allele 
into YY1CKO mice. Similar to what is shown in Figure 3.5, the GC reaction was 
impaired in YY1CKO; mT/mG mice (Figure 3.9). I found that 41.4% of GC B 
cells at day 4 post-sRBC immunization were GFP positive in YY1CKO; mT/mG 
mice compared to 56.1% in AID-Cre; mT/mG control mice. 
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deleted cannot be easily identified based on the mT/mG reporter, thus limiting 
its use to identify YY1-null GC B cells. 
 
Table 3.1 AID-Cre mediated deletion of YY1 alleles in GC B cells 
Days post 
immunization 
Deletion of both YY1 
alleles   
Deletion of only one 
YY1 allele  
No YY1 deletion  
4 73.0%  (54/74) 10.8% (8/74) 16.2% (12/74) 
10 69.6% (71/102) 8.8% (9/102) 21.6% (22/102) 
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YY1 does not affect cell proliferation but prevents apoptosis in GC B 
cells 
 The presence of small numbers of GC B cells with both YY1 alleles 
deleted suggests that YY1 is likely not required for the initiation of the GC 
reaction. The decrease in DZ cells and the decrease of GC B cells in YY1CKO 
mice from day 6 to day 10 (average of 1.5×106 cells at day 6 vs. 0.48×106 
cells at day 10) post-immunization suggest that impairment of the GC reaction 
in YY1CKO mice is due to a defect in maintaining or amplifying GC B cell 
numbers. I suspected this defect could be the result of altered proliferation 
and/or apoptosis of GC B cells in YY1CKO mice. To test this hypothesis, I first 
examined the consequence of loss of YY1 on cell proliferation and cell cycle. 
As shown in Figure 3.10A, BrdU incorporation was significantly decreased in 
GC B cells in YY1CKO mice compared to control mice (YY1Fl/Fl or AID-Cre) at 
day 10 post-sRBC immunization. In contrast, proliferation of non-GC B cells 
(B220+CD95-GL7-) or non-B cells (B220-) was low and there was no 
difference in BrdU incorporation in these cells between YY1CKO and control 
mice (Figure 3.10A). Interestingly, Ki-67 and DAPI staining indicated there 
was no significant difference in cell cycle distribution of GC B cells between 
YY1CKO and control mice (Figure 3.10B and 3.10C).   
As DZ cells undergo rapid proliferation(50, 78–80, 169), the altered 
DZ/LZ ratio in YY1CKO mice (Figure 3.7) prompted an investigation into 
whether decreased BrdU incorporation in GC B cells in YY1CKO mice was due  
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to decreased proliferation in DZ and LZ cells, or due to a decrease in DZ cells. 
I found no significant difference in BrdU incorporation in DZ or LZ cells 
between YY1CKO mice and control mice (Figure 3.10A). Because LZ cells 
proliferate slower than DZ cells and incorporate less BrdU (Figure 3.10A), 
these data argue that altered distribution of DZ and LZ cells rather than 
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Materials and Methods 
Mouse strains  
Mouse strains YY1Fl/Fl (B6;129S4-Yy1tm2Yshi/J), AID-Cre (B6.129P2-
Aicdatm2(cre)Mnz/J), mT/mG (B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo/J) and C57BL/6 wild-type were obtained from Jackson laboratories. 
Mouse studies were approved by the Institutional Animal Care and Use 
Committee of University of Massachusetts Medical School.  
 
Immunization  
Sheep red blood cells (1.5×109) (Cocalico Biologicals) were injected 
intraperitoneally into 8 to 10-week old mice of both sexes. At various days 
after immunization, spleens were collected for FACS staining, fixed in 
formalin or frozen in OCT for sectioning. 
 
Flow Cytometry 
Spleens were prepared into single cell suspension and red blood cells were 
lysed in cold distilled water. After filtered through 70-µm nylon mesh and 
counting using a MACSQuant analyzer (Miltenyi Biotec), cells were incubated 
with anti-CD16/32 antibody (BioXCell) to block Fc receptors and stained with 
fixable viability dye eFluor 780 (eBioscience). Cells were then stained for 20 
min in staining media (Hank’s balanced salt solution, 3% FBS, 0.02% sodium 
azide, 1 mM EDTA) with primary antibodies, including B220-FITC, B220-
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eVolve 655 (clone RA3-6B2), GL7-eFluor 660, GL7-eFluor 450 (clone GL7), 
CD95-PE, CD95-APC (clone 15A7) (eBioscience), PNA-biotin (Vector 
Laboratories), CD86-Pe-Cy7 (clone GL-1; BioLegend) or CD184-biotin 
(2b11/CXCR4; BD Bioscience). Cells stained with biotin-labeled antibodies 
were incubated with streptavidin-eFluor 450 (eBioscience). For intracellular 
staining, cells were stained with fixable viability dye eFluor 780, permeabilized 
and fixed using a cytofix/cytoperm plus kit (BD Bioscience) according to 
manufacturer suggested protocol. Cells were then stained with YY1 antibody 
(H-414; Santa Cruz Biotechnology) and DyLight 594-conjugated secondary 
antibody (Jackson ImmunoResearch). Flow cytometry analysis was 
performed on an LSRII FACS or a FACSAria cell sorter (BD Bioscience), and 
analyzed using FlowJo software (FlowJo). 
 
Single-cell PCR of floxed and deleted YY1 alleles 
GC B cells (B220+CD95+GL7+) were sorted into sterile water (5-10 µl) as one 
cell per well in 96-well plates. Cells were lysed by 3 freeze-thaw cycles 
followed by heating to 98°C for 10 minutes. PCR to amply the YY1 locus was 
performed using Phusion hot start flex DNA polymerase (New England 
Biolabs) and primers: P1 (5’-ACCTGGTCTATCGAAAGGAAGCAC-3’), P2 (5’- 
GCTTCGCCTATTCCTCGCTCATAA-3’), and P4 (5’- 
CCAAAGTTCGAAACCTGCTTTCCT-3’) as described(111).  
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BrdU incorporation and cell cycle analysis 
Mice were injected intraperitoneally with 1 mg BrdU. 6-16 hours later, spleen 
cells were stained for GC B cells as described above. After being fixed and 
permeabilized using a BrdU flow kit (BD Bioscience), cells were stained with 
anti-BrdU-FITC (BD Bioscience) or anti-Ki-67-PerCp-Cy5.5 (Sola15) 
(eBioscience) antibody. Cells stained for Ki-67 were further incubated with 
DAPI. Stained cells were analyzed by flow cytometry as described above. 
 
Activated Caspase-3 staining 
Spleen cells were collected and stained for GC B cells as described above. 
An active Caspase-3 apoptosis kit and anti-activated caspase-3-PE antibody 
(BD Bioscience) were used following manufacturer suggested protocol. 
Stained cells were analyzed by flow cytometry as described above. 
 
Immunofluorescence and immunohistochemistry staining 
Frozen spleen sections (5 µm) were fixed in 4% paraformaldehyde and 
extracted in 0.5% Triton-X 100. Sections were stained with PNA-biotin and 
streptavidin-DyLight 594 (Jackson ImmunoResearch). TUNEL staining was 
performed after PNA surface staining using an in situ cell death detection kit 
(Roche) following manufacturer’s recommendations. Fluorescence images 
were obtained using a microscope (Axiovert 200 Carl Zeiss, Inc.) equipped 
with a 40x objective and multi-bandpass dichroic and emission filter sets 
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(model 83000; Chroma Technology Corp.) set up in a wheel to prevent optical 
shift. Images were captured with the AxioVision software (Carl Zeiss, Inc.) 
and a camera (Orca-ER; Hamamatsu Photonics). Formalin fixed spleens 
were embedded in paraffin and sections stained with PNA-biotin. 
Immunohistochemistry images were obtained using a microscope (Axiovert 
40 CFL Carl Zeiss, Inc.) equipped with a 2.5x objective. Images were 
captured with QCapture Pro 7 software (QImaging) and a camera (QImaging 
QI Click). 
 
Cell Culture and viral infection 
Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos and 
cultured as described(144). MEFs were infected with Adeno-Cre-GFP virus 
(University of Iowa) with a multiplicity of infection of 100. Four days later, cells 
were harvested for flow cytometry and Western blotting. SU-DHL-6 cells 
infected with lentiviral shRNA targeting YY1 (V2LHS_219592, 
V2LHS_389741) and a non-silencing shRNA control (RHS4346) were 
described previously(135).  
 
Western blots 
Whole cell lysates were isolated using RIPA buffer (50 mM Tris–HCl pH 7.5, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid and 
0.02% sodium azide) plus fresh protease inhibitor complete (Roche). Lysates 
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were run on SDS–PAGE Criterion X-gel (Bio-Rad) and transferred to 
nitrocellulose membranes (GE Osmonics). Membranes were probed with 
antibodies against YY1 (H414) and β-actin (Santa Cruz Biotechnology). 
Membranes were visualized using Western lightening chemiluminescence 
detection (PerkinElmer) and ChemiDoc MP System with Image lab software 
(Bio-Rad). 
 
Statistical Analysis 
Data were presented as mean ± standard deviation. Two-tailed and unpaired 
Student’s t-test was used for pairwise comparisons with P<0.05 considered 
statistically significant. 
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CHAPTER IV: SMURF2 does not regulate the GC 
reaction 
The important role of YY1 in the GC led to the investigation of factors 
upstream of YY1 in the regulation of the GC. SMURF2 has been shown to 
mediate the ubiquitination and degradation of YY1(135, 136). SMURF2 is 
also a tumor suppressor in B cell lymphoma and has been implicated as 
prognostically significant in human DLBCL(135, 138). For these reasons I 
tested the hypothesis that Smurf2 regulates a normal GC reaction by 
suppressing the GC response. 
Results 
Smurf2-deficent mice mount a normal GC response 
Previous studies have shown that Smurf2-deficient mice have a small 
increase in splenic B cells and an increase in proliferation both in vivo and in 
response to LPS stimulation in vitro(135). Given the established role of 
Smurf2 as a tumor suppressor in B cell lymphoma and the connection 
between the GC and lymphoma, I investigated whether Smurf2 regulates the 
GC reaction. I hypothesized that Smurf2 could act as a negative regulator of 
the GC, suppressing the GC to maintain a tightly controlled response. 
Utilizing the previously described(144) Smurf2-deficient (hereafter referred to 
as Smurf2T/T) mice, I investigated the effect of decreased Smurf2 levels on 
the GC reaction. I injected Smurf2T/T and wild type mice with sRBC to induce 
GC and examined the response by flow cytometry 6, 10, or 21 days later. Day 
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Increased SMURF2 expression does not affect the GC or YY1 levels 
Given that the results of the studies using the Smurf2T/T mice indicate 
that Smurf2 is not necessary to suppress the GC reaction, I investigated 
whether Smurf2 is sufficient to suppress the GC reaction. To achieve this goal 
I utilized a mouse model in which Smurf2 cDNA is inserted downstream of a 
lox-stop-lox site in the Rosa26 locus. This construct results in ubiquitous 
Smurf2 expression in addition to endogenous levels when cre-recombinase 
mediates the recombination and deletion of the stop cassette. I crossed this 
mouse to a CD19-Cre mouse (hereafter referred to as Smurf2CKI) in which 
cre-recombinase is inserted to replace the first exon of CD19, preventing 
CD19 expression from that allele and instead expressing cre in cells which 
normally express CD19. CD19 is normally expressed in B cells starting from 
early B cell development. This results in ubiquitous expression of Smurf2 in B 
cells. I find that SMURF2 protein levels are increased 16.5 fold in CD19+ 
isolated splenocytes from Smurf2CKI over CD19+ isolated splenocytes from 
CD19-Cre control mice (Figure 4.4A). However, despite this dramatic 
increase in SMURF2 protein, I found no change in levels of YY1 protein 
(Figure 4.4A). This suggests that SMURF2 levels are likely not the limiting 
factor in mediating YY1 degradation.  
Utilizing these mice with high SMURF2 levels in the B cells, I 
investigated the peak of the GC response at day 10 post-sRBC immunization. 
I found no alteration in frequency or number of GC B cells (Figure 4.4B), 
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Immunization  
Sheep red blood cells (1.5×109) (Cocalico Biologicals) were injected 
intraperitoneally into 8 to 10-week old mice of both sexes. At various days 
after immunization, spleens were collected for FACS staining. 
Flow Cytometry 
Mouse spleens were prepared into single cell suspension and red blood cells 
were lysed in cold distilled water. After filtering through 70-µm nylon mesh 
and counting using a MACSQuant analyzer (Miltenyi Biotec), cells were 
incubated with anti-CD16/32 antibody (BioXCell) to block Fc receptors. Cells 
were then stained for 20 min in staining media (Hank’s balanced salt solution, 
3% FBS, 0.02% sodium azide, 1 mM EDTA) with primary antibodies, 
including B220-FITC (clone RA3-6B2), GL7-eFluor 660 (clone GL7), CD95-
PE (clone 15A7) (eBioscience), CD86-Pe-Cy7 (clone GL-1; BioLegend) or 
CD184-biotin (2b11/CXCR4; BD Bioscience). Cells stained with biotin-labeled 
antibodies were incubated with streptavidin-eFluor 450 (eBioscience). Flow 
cytometry analysis was performed on an LSRII FACS or a FACSAria cell 
sorter (BD Bioscience), and analyzed using FlowJo software (FlowJo). 
Western blots 
Whole cell lysates were isolated using RIPA buffer (50 mM Tris–HCl pH 7.5, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid and 
0.02% sodium azide) plus fresh protease inhibitor complete (Roche). Lysates 
were run on SDS–PAGE Criterion X-gel (Bio-Rad) and transferred to 
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nitrocellulose membranes (GE Osmonics). Membranes were probed with 
antibodies against SMURF2 (EP629Y3) (Abcam), YY1 (H414) and β-ACTIN 
(Santa Cruz Biotechnology). Membranes were visualized using Western 
lightening chemiluminescence detection (PerkinElmer) and ChemiDoc MP 
System with Image lab software (Bio-Rad). 
Magnetic bead isolation of CD19+ cells 
Cells were processed to single cell suspension and red blood cells were lysed 
as described above. Cells were incubated with anti-CD16/32 antibody to 
block Fc receptor as above. Cells were incubated with anti-CD19-Biotin 
antibody (ebioscience) and anti-biotin MACS microbeads following 
manufacturer’s recommendations (Militenyi Biotec). Samples were then run 
on autoMACS Pro Separator (Militenyi Biotec) to achieve separation of CD19+ 
containing fraction. These cells were washed with PBS and processed as 
above to isolate whole cell lysate. 
Gene Expression Analysis 
Utilizing the publically available dataset GSE68043(48) the values for Smurf2 
probes (1429045_at, 1429046_at, 1454894_at) for all three control DZ and 
three control LZ samples were obtained. These values represent log2 
transformed intensity values from Affymetrix Mouse Genome 430 2.0 Array 
platform. The values for all Smurf2 probes were averaged across all three DZ 
or LZ samples and mean with standard deviation was plotted. 
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SHM analysis 
GC B cells (B220+, GL7+, CD95+) were FACS sorted on day 10 post-sRBC 
immunization. From these sorted cells DNA was isolated by incubating in 100 
µl STE (0.1M NaCl, 20mM Tris pH 8.0, 1mM EDTA) with 100 µg proteinase K 
and SDS (2.5 µl of 20%) for 2 hours at 55°C. Samples were then cooled to 
room temperature and 100 µM sodium acetate at pH 5.2 and 95% ethanol 
was added. After incubating overnight at -20°C, DNA was pelleted and 
supernatant replaced with 70% ethanol. The precipitated DNA was then 
pelleted again and resuspended in water. PCR was performed using hotstart 
Phusion DNA polymerase (New England BioLabs Inc.) and the following 
primers: JH4-Fwd: 5’-AGC CTG ACA TCT GAG GAC-3’; JH4-Rev: 5’-GTG 
TTC CTT TGA AAG CTG GAC-3’(172). The resulting DNA was separated on 
a 1% agarose gel and the ~600BP band was visualized using crystal violet 
staining and excised. The DNA was purified using Qiagen gel extraction kit. 
To facilitate quick cloning dA overhangs were added using taq polymerase. 
The resulting DNA was cloned using TOPO TA-cloning kit (ThermoFisher 
Scientific) following manufacturer recommendations. The resulting cloned 
DNA was transformed into XL-10 competent cells and colony sequencing was 
performed (Macrogen USA). Resulting sequences were aligned using 
ClustalW. Sequences were included in further analysis only if they were 
unique clones and if they contained at least one mutation. Python 2.7.8 was 
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used to compare aligned sequences to consensus sequence and determine 
the number and type of mutations for each clone.  
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CHAPTER V: Discussion 
Inhibition of bromodomain proteins is effective for the treatment of 
human diffuse large B cell lymphoma 
In chapter II of this thesis, I demonstrated that targeting BRD proteins 
by JQ1 in human DLBCL cells resulted in cell death or cell senescence. 
Sensitivity to JQ1 treatment was found in various molecular subtypes of 
DLBCL (ABC or GCB) and with various status of the C-MYC or BCL2 locus 
(translocated, amplified or unchanged), suggesting that JQ1 has a broad 
effect in DLBCL. This broad effect is especially encouraging for the potential 
clinical utility of JQ1 for the treatment of DLBCL. Recent studies have found 
anti-proliferative and pro-apoptotic effects of JQ1, particularly in 
hematopoietic malignancies, and these effects of JQ1 are primarily mediated 
through inhibition of C-MYC(100–102, 104, 105, 107, 109, 153, 154). 
Consistent with these findings, I showed that JQ1-mediated suppression of C-
MYC expression, regardless of whether it is from an un-perturbed C-MYC loci 
(HLY-1, OCI-Ly10, RC-K8, and SU-DHL-5), or from a chromosomally-
translocated (HBL-1, OCI-Ly8, OCI-Ly18, SU-DHL-6, and SU-DHL-10), or 
amplified (OCI-Ly3 and SU-DHL-4) loci. Collectively, my studies suggest that 
inhibition of C-MYC via BET bromodomain family proteins by JQ1 provides a 
promising therapeutic model for patients with DLBCL. 
Previously it had been shown that cancer cells respond to JQ1 
primarily with rapid cell cycle arrest and apoptosis(100–102, 104, 107, 109, 
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173). These studies demonstrate increased apoptotic markers within 2-3 days 
of JQ1 treatment. I found two distinct phenotypes in response to JQ1: 
senescence or apoptosis. OCI-Ly8 cells displayed G1 arrest and positive 
staining for SA-β-gal without increases in sub-G1 population and apoptosis 
following JQ1 treatment, indicating that senescence is the main response to 
JQ1 in OCI-Ly8 cells. SU-DHL-4 and SU-DHL-10 cells showed little or no 
positive SA-β-gal staining but increased sub-G1 population and apoptosis, 
indicating that apoptosis is the prominent response to JQ1 in these two cell 
lines. Both apoptosis and senescence were observed in OCI-Ly3 cells. The 
apoptosis versus senescence phenotype did not correlate with the 
parameters that I examined, including molecular subtype (ABC: OCI-Ly3 vs. 
GCB: OCI-Ly8, SU-DHL-4 and SU-DHL-10), p53 mutation status (wild type: 
OCI-Ly3 vs. mutated: OCI-Ly8), C-MYC translocation and expression level 
(unperturbed: SU-DHL-4; amplified: OCI-Ly3; translocated: SU-DHL-10 and 
OCI-Ly8), BCL2 translocation status (translocated: SU-DHL-4, SU-DHL-
10(160) and OCI-Ly8(159); amplified: OCI-Ly3(159)), or expression of p16, 
p21, p53, Rb or BCL-XL.  
In this study I utilized doxorubicin as a positive control for induction of 
apoptosis in these cell lines. As doxorubicin is a component of R-CHOP 
therapy it is interesting to consider if JQ1, by comparison, truly could provide 
additional therapeutic advantages. It is difficult to directly compare the two 
therapies in vitro with their potential efficacies in vivo. The effective dose of 
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doxorubicin in cell culture is likely much higher than could be realistically 
achieved in patients given the high toxicities associated with 
chemotherapeutic agents such as doxorubicin. Unfortunately, the NSG 
mouse model utilized in this study is not amenable to studies of doxorubicin in 
vivo compared with JQ1. NSG mice are not able to tolerate doxorubicin, 
making direct comparisons between the two drugs in vivo in this mouse 
model not feasible. This suggests there is potential value to JQ1 in treatment 
of DLBCL, especially given its lack of apparent adverse effects. As discussed 
below, combination therapies with JQ1 and doxorubicin appear to be 
promising, further solidifying the potential value of continued studies of JQ1 in 
DLBCL. 
A recent study revealed highly asymmetric loading of BRD4 at super-
enhancers in DLBCL cells. These super-enhancers and genes that they 
regulate are particularly sensitive to JQ1 inhibition, explaining the selective 
effect of JQ1 on oncogenic and lineage-specific transcriptional circuits(110). It 
will be interesting to understand how this selectivity of BRD4 loading at super-
enhancers and inhibition by JQ1 are responsible for the different responses 
(apoptosis vs. senescence) to JQ1 in DLBCL cells. 
I showed that JQ1 significantly suppresses growth of DLBCL cells 
engrafted in NSG mice and improves survival of tumor-bearing mice, 
demonstrating a potential use of JQ1 in treatment of DLBCL. I found that JQ1 
alone with single daily dosing of 50mg/kg for 21 days was not sufficient to 
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cure the disease. The differences in JQ1 effectiveness observed between in 
vitro and in vivo studies could be due to a number of issues, one of which is 
bioavailability in vivo. The half-life of JQ1 in plasma is relatively low: 0.9 hours 
(intravenous injection of 5 mg/kg) or 1.4 hours (oral administration of 10 
mg/kg(100)). When dosed every 24 hours, it is likely that very little JQ1 
remains after 8 hours. Although it has not been previously measured, the 
effective concentration of JQ1 at the site of tumors is likely even lower than in 
the plasma, because the typically poor vasculature in tumor tissues could 
prevent JQ1 from being effectively delivered to the tumor cells. A recent study 
using 2 daily doses of JQ1 treatment for 30 days (vs. 1 daily dose for 21 days 
in our study) shows a median survival advantage of 9 days(110) compared to 
4 days in our study, suggesting that more frequent dosing to maintain plasma 
concentration of JQ1 over time may increase its effectiveness in vivo, 
especially given that no adverse effects have been reported for JQ1 use in 
mouse models. Additional modifications to the structure of JQ1 that maintain 
its specificity while increasing the half-life will make JQ1 more effective in vivo 
and in clinical use. 
It is possible to combine JQ1 with the current standard therapy to 
increase the efficacy of treatment. A recent study by Emadali and colleagues 
showed that the addition of JQ1 to Rituximab increases sensitivity of 
Rituximab-resistant DLBCL cell lines(154). This study provides proof-of-
principal that adding JQ1 to current treatments may be beneficial to patients 
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with DLBCL. Another study has demonstrated the value of JQ1 in 
combination with other novel therapies for DLBCL. Zhao and colleagues 
showed that treating DLBCL cell lines with EZH2-inhibitor DZNep and JQ1 
reduces cell viability in a synergistic manner(153) . I propose that JQ1 should 
be examined clinically in patients with DLBCL. I speculate that the addition of 
JQ1 as a component of salvage therapy or even potentially added to R-CHOP 
therapy, may result in the effective treatment of DLBCL. Continued 
examination of JQ1 alone and in combination with other novel therapeutic 
agents is warranted. 
Recent advances in BET inhibition 
 In the past few years, advancements have been made which have built 
upon the work published from Chapter II of this thesis. The major areas these 
advancements have focused on include mechanisms of potential resistance 
and combination treatments. Xu and colleagues have shown that the 
apoptosis induced by JQ1 or other BET family inhibitors requires the 
repression of the miR 17-92 family which in turn drives Bim expression, 
leading to apoptosis; Bim is required for apoptosis in this context. The authors 
suggest that overexpression of BCL2, a potent anti-apoptotic factor, or 
inactivation of Bim may be a potential mechanism for resistance to apoptosis 
induced by JQ1-like molecules(174). Although in the study described in 
Chapter II I did not investigate the protein levels of BCL2, my results may be 
in contrast to the suggested resistance to apoptosis when BCL2 is 
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overexpressed. Of the cell lines selected for advanced study, three (Oci-Ly8, 
SU-DHL-4, and SU-DHL-10) have documented BCL2 translocations(159, 
160), while the fourth (Oci-Ly3) has a documented amplification of 
BCL2(159). While all four of these cell lines likely have overexpression of 
BCL2 given the cytogenetic abnormalities, two (Oci-Ly3 and Oci-Ly8) respond 
to JQ1 treatment by preferentially senescing with only low levels of apoptosis, 
while the remaining two (SU-DHL-4 and SU-DHL-10) have high levels of 
apoptosis. If the hypothesis that BCL2 overexpression prevents JQ1-induced 
apoptosis is correct, these cells must have low BCL2 levels, despite the 
documented BCL2 translocations.  
Ceribelli and colleagues focused on the role of BET inhibitors in ABC 
subtype DLBCL. They showed that the combination of BET inhibition with 
ibrutinib, a BTK inhibitor, results in the synergistic killing of ABC DLBCL both 
in vitro and in mouse xenografts(175). Cinar and colleagues focused on 
combination treatments in the difficult to treat double or triple-hit lymphoma. 
Double and triple-hit lymphomas have translocations of C-MYC, BCL2, and/or 
BCL6 (two events for double-hit, all three for triple-hit) and are considered 
aggressive and have a poor prognosis. Cinar and colleagues showed that the 
combination of BCL2 inhibition and C-MYC inhibition (with BET inhibitors) 
suppressed growth in double and triple-hit lymphomas better than single 
treatments alone. They additionally showed that combination therapy with 
vincristine or doxorubicin (components of the standard of care, R-CHOP) and 
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BET inhibition or BCL2 inhibition was additive(176). The synergistic effect of 
BCL2 and C-MYC inhibition in double-hit lymphoma was independently 
confirmed(177). These recent studies have provided advancements on the 
work presented in Chapter II, and underscore the important nature of that 
work. 
 
YY1 regulates the GC reaction by inhibiting apoptosis and maintaining 
DZ 
As described in Chapter III of this thesis, I selectively deleted YY1 in 
GC B cells using AID-Cre and found that loss of YY1 significantly impaired 
the GC reaction as indicated by decreased frequency and number of GC B 
cells in spleen in response to sRBC immunization. The decrease in GC B 
cells was observed as early as day 4 post-sRBC immunization and 
exacerbated throughout the GC reaction (Figures 3.5 and 3.6). Previously, 
YY1 has been implicated as a regulator of the GC reaction based on the 
enrichment of YY1 target genes in the GC B cell-specific transcriptional 
signature(51). A study published after the completion of this experimental 
work provided evidence that deletion of YY1 results in a dramatic reduction in 
GC B cells(127). Now our studies provide additional experimental evidence 
indicating that YY1 is required for a normal robust GC reaction. Because the 
AID-Cre allele that was used is activated in GCs around day 4 after antigen 
encounter (Figure 3.3), I cannot completely rule out the possibility that 
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deleting YY1 in naïve mature B cells before antigen encounter will affect the 
commitment of these cells to become GC B cells. However, our finding that 
~70% of the remaining GC B cells in YY1CKO mice at day 4 or day 10 after 
immunization had both YY1 alleles deleted (Table 3.1) suggests that YY1 is 
not necessarily required for the initiation of the GC reaction, but rather is 
required to maintain a robust GC reaction.  
To understand the defects in the GC reaction in the absence of YY1, I 
investigated whether loss of YY1 affected proliferation of GC B cells, as YY1 
has been shown to regulate proliferation in MEFs or HeLa cells(115). GC B 
cells in YY1CKO mice showed a significant decrease in BrdU incorporation 
compared to GC B cells in control mice (Figure 3.10A). However, Ki-67 and 
DAPI staining indicated there was no significant difference in cell cycle 
distribution in GC B cells between YY1CKO and control mice (Figure 3.10B and 
3.10C), suggesting that YY1 does not directly affect proliferation of GC B 
cells. This finding is consistent with a previous report that ablation of YY1 in 
splenic B cells activated by lipopolysaccharide ex vivo does not alter cell 
division and proliferation(112). I further found that loss of YY1 resulted in a 
decrease of DZ cells and a concomitant increase in LZ cells (Figure 3.7). In 
DZ, GC B cells undergo rapid cell proliferation(50, 80, 169). I found that there 
was no significant difference in BrdU incorporation in DZ or LZ cells between 
YY1CKO mice and control mice. These results argue that YY1 does not directly 
affect proliferation of GC B cells, but rather the altered distribution of DZ and 
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LZ cells is responsible for the decreased BrdU incorporation in GC B cells of 
YY1CKO mice.  
My finding that YY1 regulates the relative distribution of DZ and LZ in 
GCs is intriguing, as not much is known about how GC polarity is regulated. A 
large body of work supports a model in which GC B cells transit between DZ 
and LZ to undergo SHM in DZ and affinity selection as well as CSR in LZ(33, 
80). It has been shown that DZ cells express high levels of CXCR4 and 
CXCR4 deficiency leads to an absence of DZ without altering the size and 
number of GCs(178, 179). More recently, two groups independently found 
that FOXO1 and phosphoinositide-3 kinase (PI3K) play a critical role in GC 
polarity(47, 48). FOXO1 is highly expressed in DZ, and its activity is down 
regulated in LZ. Deletion of FOXO1 or activation of PI3K results in a loss of 
DZ with LZ-only GCs, partly due to down-regulation of CXCR4(47, 48). In 
addition, a small number of LZ cells were found to express FOXO1 and C-
MYC(48). C-MYC is required to initiate the GC reaction and the re-entry of LZ 
cells into DZ for additional rounds of SHM(94, 95). FOXO1 is likely involved in 
both regulation of targets necessary for the formation of DZ and the cyclic re-
entry of LZ cells into DZ. The latter function is possibly through up-regulation 
of c-Myc. YY1 has been found to transactivate c-Myc(119, 120) in splenic B 
cells(135). It is plausible that YY1-mediated transactivation of c-Myc plays a 
similar role in the re-entry of LZ cells into the DZ. Loss of YY1 would impair 
the re-entry of LZ cells, leading to decreased DZ cells in YY1CKO mice. 
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At day 10 post-immunization, the frequency and number of GC B cells 
in YY1CKO mice continued to decrease by 3-fold compared to day 6, while 
control mice had largely maintained their GC B cells (Figure 3.5C). Apoptosis 
was increased in GC B cells in the absence of YY1 (Figure 3.11), providing a 
plausible mechanism for the reduction of GC B cells in YY1CKO mice. The GC-
specific transcriptional profile is enriched for genes involved in cell death(51).  
In particular, the BCL2 family anti-apoptotic protein MCL1, which is 
upregulated in GC B cells, is a potential transactivation target of YY1(51). 
MCL1 has been shown to be the pro-survival factor in GCs. It is required for 
survival of GC B cells and essential for GC formation(63). It will be interesting 
to investigate whether Mcl1 is the critical downstream target through which 
YY1 regulates the survival of GC B cells.  
The GC reaction is not only critical in order to produce high-affinity 
antibodies for a robust adaptive immune response, but it also can lead to 
pathogenesis of B-cell lymphoma. Because of their high proliferation rate and 
highly mutagenic processes, GC B cells are susceptible targets of B-cell 
malignancies. Most non-Hodgkin’s lymphomas are derived from GC B cells or 
B cells that have passed through GCs(80, 84–87). My finding that 
dysregulation of YY1 leads to an impaired GC reaction suggests a potential 
oncogenic role for YY1 in lymphomagenesis. Consistent with this notion, the 
expression of YY1 is increased significantly in human DLBCL, Burkitt’s 
lymphoma, and follicular lymphoma compared to reactive lymph nodes or 
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normal B cells(129–131). Further, high levels of YY1 expression correlate 
with a worse survival prognosis in human DLBCL and follicular lymphoma 
patients(130, 131).  
 
SMURF2 does not regulate the GC 
In Chapter IV of this thesis, I demonstrated that SMURF2 does not 
have a clear role in the GC. I showed that Smurf2-deficiency does not alter 
the number or frequency of the GC regardless of when during the reaction I 
examined (day 6, 10, or 21). I also showed that the DZ and LZ populations 
are not perturbed by the loss of Smurf2. I had hypothesized that decreased 
Smurf2 would result in an increase in the GC number and frequency or 
extend the persistence of the reaction. Any of these phenotypes would 
suggest SMURF2 has a role in suppressing the GC. Additionally, an increase 
in GC B cells or an extension of the persistence of the reaction would provide 
a logical mechanism for the increased incidence of B cell lymphoma observed 
in these mice. Given that I did not observe any alteration in the GC reaction in 
the Smurf2T/T mice, I must accept that these hypotheses are not correct.  
In trying to understand the underlying mechanism that renders Smurf2 
a tumor suppressor, I tested the hypothesis that loss of Smurf2 would 
increase the SHM frequency. An increased SHM frequency would likely 
correlate with increased non-Ig, “off-target” mutation frequency. This would 
provide a logical mechanism for the increased likelihood of cancer in 
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Smurf2T/T mice. Although this provides an attractive, logical hypothesis, 
unfortunately the data suggest that decreased Smurf2 does not alter SHM.  
Based on the data gathered from Smurf2T/T mice, it appears that 
Smurf2 loss-induced lymphoma is not caused by an underlying increase in 
the GC, increase in SHM, alteration in the DZ and LZ polarity of the GC, or a 
more persistent GC reaction (as indicated by day 21 post-immunization). This 
leaves an open question as to the underlying mechanism that renders 
SMURF2 a tumor suppressor. One possibility proposed in the past is that the 
decrease in senescence in Smurf2T/T mice may be sufficient to render these 
mice more vulnerable to tumorigenesis. Previous work has shown a decrease 
in senescent cells in the spleens of Smurf2T/T mice as well as an increased 
likelihood for MEFs from these mice to become immortalized(144). A 
decrease in senescence may allow cells with DNA damage or other issues 
that would normally cause them to become post-mitotic and senescent to 
instead continue to proliferate and accumulate additional mutations. Another 
likely mechanism underlying the increased tumorigenesis in Smurf2T/T mice is 
that there is simply an increase in proliferation of B cells in these mice(135). 
Increased proliferation is a hallmark of cancer(180) and is often an initiating 
step in tumorigenesis, which provides an increase in potential target cells for 
additional mutations. In addition to the evidence that B cells are more 
proliferative in Smurf2T/T mice, it has also been shown that as these mice age 
the hematopoietic stem cells are more proliferative and do not display the 
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skewing away from the lymphoid lineages that is normally seen in aged 
mice(145). This may suggest that as these mice age, there are more B cells, 
providing more potential target cells for mutations and subsequent 
transformation. Finally, Blank and colleagues suggest that SMURF2 acts as a 
tumor suppressor by regulating genomic stability through its regulation of 
RNF20(138). Although the studies presented in this thesis serve to rule out 
some possible hypotheses for the tumor suppressive role for SMURF2, I 
cannot distinguish between the other possibilities presented here or others 
that have not been considered. 
In Chapter III of this thesis I showed that loss of YY1 disrupts the GC 
and leads to greatly diminished frequency and number of GC B cells. I 
investigated whether SMURF2 could be an important upstream regulator of 
YY1 in this context. In order to test the hypothesis that increased SMURF2 
would decrease YY1 and mimic the phenotypes observed in Chapter III I 
utilized the Smurf2CKI mice. I first showed that the 16-fold increase in 
SMURF2 protein in these mice is not sufficient to alter the YY1 protein levels. 
It is currently unclear why this is the case, but it is possible that SMURF2 is 
not the limiting factor in the ubiquitination and degradation of YY1, therefore 
simply increasing SMURF2 may not alter its ability to degrade YY1. Although 
previous work in our lab has shown that YY1 is increased in the spleens of 
Smurf2T/T mice(135), it is possible that YY1 is not regulated by SMURF2 in 
the CD19+ B cells that I investigated in Figure 4.4. It is also possible that 
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although a decrease in SMURF2 protein increases YY1, that the subsequent 
increase in SMURF2 may not have the reciprocal effect. Previous work has 
shown that increased expression of SMURF2 in a human DLBCL cell line 
does decrease YY1 protein level by about 50%(135). SMURF2 has an 
autoinhibitory function, mediated by the interaction between the C2 and 
HECT domains, which leads to inhibition of activity but stabilization of 
SMURF2 protein(181). This could be the reason I observe very high levels of 
SMURF2 protein but no apparent indication of increased SMURF2 activity. 
This conclusion would be strengthened by investigation of protein levels of 
additional SMURF2 targets. Given the possibility that this increased SMURF2 
may still be functioning, and simply not targeting YY1, I investigated the 
frequency and number of GC B cells in these mice 10 days after sRBC 
immunization. I found no alteration in the GC in these mice, suggesting that 
either increased SMURF2 expression does not increase the SMURF2 activity 
in the cell, or that increased SMURF2 does not affect the GC. This highlights 
the need for an easy and effective assay to determine SMURF2 activity within 
the cell. 
 
SMURF2-YY1-C-MYC as a pathway in lymphoma 
Throughout this thesis I have demonstrated supporting evidence that 
the SMURF2-YY1-C-MYC axis is important to the development of lymphoma. 
In Chapter III I showed that YY1 has an essential role in maintaining the 
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normal GC reaction. Given the established link between the GC and DLBCL 
development, this result has implications for therapeutics. Understanding the 
underlying basic biological processes that occur in cells that go on to develop 
cancer can provide insight into new avenues for treatment and prevention. In 
this case, the essential nature of YY1 in the GC and the fact that it is often 
highly expressed in DLBCL, suggests a link worth exploring in the context of 
lymphoma. It seems possible that inhibition of YY1 may be effective in the 
context of cancer, especially given our result that YY1 appears to decrease 
apoptosis in GC B cells. When pursing this hypothesis investigators should 
also consider the potential detrimental effects loss of YY1 may have on the 
adaptive immune system, particularly in the context of older patients or those 
who may be experiencing other treatments that make them at increased 
susceptibility to infection. Although no YY1-specific inhibitors have been 
developed, evidence suggests that the anti-CD20 antibody, rituximab, which 
is part of R-CHOP standard of care, acts partially by inhibiting YY1(182).  
Another way to utilize the data presented in Chapter III to suggest 
therapeutically relevant targets would be to consider possible downstream 
effectors of YY1. In particular, I demonstrated that YY1 promotes survival in 
GC B cells, suggesting YY1 could play a similar role in lymphoma. I suggest 
that YY1 may prevent apoptosis by activating transcription of the essential 
pro-survival factor Mcl1. MCL1 has been demonstrated as a resistance factor 
for BCL2 inhibition in lymphoma(183). Recently Leverson and colleagues 
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identified a MCL1 inhibitor that is effective in various cancer cell lines, both 
independently and in concert with BCL2 inhibitors(183). This could provide a 
potential therapeutic intervention downstream of high YY1 expression. This 
highlights the importance of understanding the underlying biological 
processes and the potential for this information to help identify relevant 
therapeutic targets in cancer. 
 Given that I also suggest the activation of c-Myc by YY1 may be 
important for the phenotypes observed in Chapter III, targeting of c-Myc 
therapeutically may be another avenue worth pursuing. As I demonstrated in 
Chapter II, inhibition of C-MYC indirectly by JQ1 is effective in inhibiting 
DLBCL cell line growth, regardless of the mechanism leading C-MYC to 
become oncogenic. It has been previously shown that SMURF2 can inhibit C-
MYC indirectly through direct inhibition of YY1 and that exogenous 
expression of SMURF2 in a human DLBCL cell line can decrease c-Myc 
levels(135). Therefore, another possible method for inhibition of C-MYC could 
be through the activation of SMURF2. I have begun to pursue efforts to 
therapeutically modulate SMURF2 expression, although to date no small 
molecules have been validated. 
 In Chapter IV I showed that SMURF2 does not exert its tumor 
suppressor activity by suppressing the GC. This suggests that the SMURF2-
YY1-C-MYC axis is not be the only important pathway that SMURF2 utilizes 
for its tumor suppressive activity. It is likely that the SMURF2-YY1-C-MYC 
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axis plays a role in tumor suppression that is independent of the role for YY1 
and C-MYC in the GC. The precise mechanism for SMURF2 as a tumor 
suppressor and what downstream effectors may be important has yet to be 
determined. This will be an interesting area for future work. 
 
Future Directions 
The three areas of focus covered in this thesis provide starting points 
for interesting future investigation. The results in Chapter II have already 
provided a baseline for further investigation in the field. Therefore the 
proposed areas for further study will focus on the other two chapters. The 
work focused on YY1 as a factor in the GC should be expanded to investigate 
the mechanism by which YY1 exerts its effect. Future work should focus on 
how YY1 regulates the GC with particular focus on Mcl1 and c-Myc as factors 
I have hypothesized may be involved. It will also be interesting to investigate 
what may occur upstream of YY1 to induce upregulation as cells commit to 
GC B cells. One hypothesis is that SMURF2 activity may decrease allowing 
YY1 protein to accumulate. Along the same lines, it would be interesting to 
investigate if overexpression of YY1 increases the GC. Given that YY1 is 
highly expressed in some lymphomas it would also be interesting to 
investigate if overexpression of YY1 in GC cells causes lymphoma. These 
two lines of investigation could be studied by utilizing a YY1 transgene to 
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model enforced expression with a possible REPO-domain deleted transgene 
as a control to probe the role of PRC recruitment in these processes.  
 In addition to investigating the involvement of YY1 in these various 
processes, it will be important to continue the work characterizing SMURF2 
as a tumor suppressor. Although previously it has been established SMURF2 
is a tumor suppressor(138, 144), the mechanism through which SMURF2 
functions is still not clear. In Chapter IV I established that SMURF2 does not 
appear to have a role in the GC or in altering the mutation rate. This leaves 
many possible mechanisms to explore, some of which are discussed above. 
Identifying the mechanism through which SMURF2 acts as a tumor 
suppressor will advance our understanding of how SMURF2 loss contributes 
to tumorigenesis and may help identify potential therapeutic opportunities. 
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